A Scientometric Analysis of Research Trends on Targeting MTOR in Breast Cancer from 2012 to 2022

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Aug 28

PMID 37637052

Authors

Xizhou Zhang

Jinyao Wu

Qiuping Yang

Huiting Tian

Lingzhi Chen

Daitian Zheng

Zeqi Ji

Jiehui Cai

Yexi Chen

Zhiyang Li

Affiliations

Soon will be listed here.

Abstract

Over the past decade, thousands of articles have been published on the mechanistic target of rapamycin (mTOR) and its role in breast cancer. However, the variability and heterogeneity of academic data may impact the acquisition of published research information. Due to the large number, heterogeneity, and varying quality of publications related to mTOR and breast cancer, sorting out the present state of the research in this area is critical for both researchers and clinicians. Therefore, scientometric techniques and visualization tools were employed to analyze the large number of bibliographic metadata related to the research area of mTOR and breast cancer. The features of relevant publications were searched from 2012 to 2022 to evaluate the present status of research and the evolution of research hotspots in this particular field. Web of Science was utilized to extract all relevant publications from 2012 to 2022. Subsequently, Biblioshiny and VOSviewer were utilized to obtain data on the most productive countries, authors, and institutions, annual publications and citations, the most influential journals and articles, and the most frequently occurring keywords. In total, 1,471 publications were retrieved, comprising 1,167 original articles and 304 reviews. There was a significant rise in publications between 2015 and 2018, followed by a sharp decline in 2019 and a rebound since then. The publication with the highest number of citations was a 2012 review authored by Baselga et al. The United States had the highest number of publications, citations and connections among all countries. Oncotarget had the highest number of published articles among all the journals, and José Baselga had the strongest links with other authors. Excluding the search topics, the most frequently used words were "expression" (n = 297), "growth" (n = 228), "activation" (n = 223), "pathway" (n = 205), and "apoptosis" (n = 195). mTOR is crucially involved in breast cancer pathogenesis, but its exact mechanism of action remains controversial and warrants further investigation. The scientometric analysis provides a distinct overview of the existing state of research and highlights the topical issues that deserve further exploration.

References

Zhao H, Cui K, Nie F, Wang L, Brandl M, Jin G . The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models. Breast Cancer Res Treat. 2011; 131(2):425-36. DOI: 10.1007/s10549-011-1420-7. View

Laplante M, Sabatini D . mTOR signaling in growth control and disease. Cell. 2012; 149(2):274-93. PMC: 3331679. DOI: 10.1016/j.cell.2012.03.017. View

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Alvarez R, Bechara R, Naughton M, Adachi J, Reuben J . Emerging Perspectives on mTOR Inhibitor-Associated Pneumonitis in Breast Cancer. Oncologist. 2018; 23(6):660-669. PMC: 6067931. DOI: 10.1634/theoncologist.2017-0343. View

Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero J, Freyer G . Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012; 30(22):2718-24. DOI: 10.1200/JCO.2011.39.0708. View

Khan M, Jain V, Rizwanullah M, Ahmad J, Jain K . PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges. Drug Discov Today. 2019; 24(11):2181-2191. DOI: 10.1016/j.drudis.2019.09.001. View

Massihnia D, Galvano A, Fanale D, Perez A, Castiglia M, Incorvaia L . Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway. Oncotarget. 2016; 7(37):60712-60722. PMC: 5312414. DOI: 10.18632/oncotarget.10858. View

Zoncu R, Efeyan A, Sabatini D . mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2010; 12(1):21-35. PMC: 3390257. DOI: 10.1038/nrm3025. View

Baselga J, Campone M, Piccart M, Burris 3rd H, Rugo H, Sahmoud T . Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2011; 366(6):520-9. PMC: 5705195. DOI: 10.1056/NEJMoa1109653. View

10.

Butrous G . International cooperation to promote advances in medicine. Ann Thorac Med. 2009; 3(3):79-81. PMC: 2700441. DOI: 10.4103/1817-1737.41913. View

11.

Grabinski V, Brawley O . Disparities in Breast Cancer. Obstet Gynecol Clin North Am. 2022; 49(1):149-165. DOI: 10.1016/j.ogc.2021.11.010. View

12.

Prvanovic M, Nedeljkovic M, Tanic N, Tomic T, Terzic T, Milovanovic Z . Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer. Life (Basel). 2021; 11(11). PMC: 8621563. DOI: 10.3390/life11111247. View

13.

Sevinc A . Web of science: a unique method of cited reference searching. J Natl Med Assoc. 2004; 96(7):980-3. PMC: 2568431. View

14.

Newman L, Martin I . Disparities in breast cancer. Curr Probl Cancer. 2007; 31(3):134-56. DOI: 10.1016/j.currproblcancer.2007.01.003. View

15.

von Bohlen Und Halbach O . How to judge a book by its cover? How useful are bibliometric indices for the evaluation of "scientific quality" or "scientific productivity"?. Ann Anat. 2011; 193(3):191-6. DOI: 10.1016/j.aanat.2011.03.011. View

16.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

17.

Ito K, Ogata H, Honma N, Shibuya K, Mikami T . Expression of mTOR Signaling Pathway Molecules in Triple-Negative Breast Cancer. Pathobiology. 2019; 86(5-6):315-321. DOI: 10.1159/000503311. View

18.

Jerusalem G, Fasolo A, Dieras V, Cardoso F, Bergh J, Vittori L . Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2010; 125(2):447-55. DOI: 10.1007/s10549-010-1260-x. View

19.

Nooshinfar E, Safaroghli-Azar A, Bashash D, Akbari M . Melatonin, an inhibitory agent in breast cancer. Breast Cancer. 2016; 24(1):42-51. DOI: 10.1007/s12282-016-0690-7. View

20.

van Eck N, Waltman L . Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010; 84(2):523-538. PMC: 2883932. DOI: 10.1007/s11192-009-0146-3. View